Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells.
To overcome the limitations of balloon expandible metal stent-induced neointimal smooth muscle cell proliferation, drug-coated stent devices have been developed. Drug eluting stents release high concentrations of antiproliferative agents, such as paclitaxel, to reduce neointimal hyperplasia. The proinflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha), is known to cause severe endothelial dysfunction and accelerate atherosclerotic lesion progression. The interaction of TNF-alpha and paclitaxel on the release of prothrombotic molecules was examined in endothelial cells. Treatment of endothelial cells with paclitaxel had no direct effect on tissue factor (TF) expression, but TNF-alpha increased TF. Cotreatment of paclitaxel with TNF-alpha markedly augmented the release of TF. TNF-alpha induced release of plasminogen activator inhibitor but no synergism occurred with paclitaxel. Treatment of endothelial cells with paclitaxel and TNF-alpha reduced expression of thrombomodulin and protein C receptor. Tissue factor pathway inhibitor expression was reduced by prolonged treatment with either paclitaxel or TNF-alpha. The adhesion molecule, CD62 E, was induced by TNF-alpha; however, CD31, CD62 P, and CD106 were not affected by paclitaxel and TNF-alpha. Apoptosis was not observed with cotreatment of endothelial cells with paclitaxel and TNF-alpha. CD59-positive microparticles were released in response to TNF-alpha, but the release was not augmented by paclitaxel. Paclitaxel and TNF-alpha increased the nitrotyrosination of proteins. These findings indicate that paclitaxel enhances TNF-alpha-induced release of TF, and downregulated thrombomodulin, increased protein nitration, which may subsequently favor prothrombotic intimal surface.
Wood
Steven C
SC
Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, FDA, Silver Spring, MD 20993-0002, USA. steven.wood@fda.hhs.gov
Tang
Xing
X
Tesfamariam
Belay
B
D002478:Cells, Cultured; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology; D009566:Nitrates / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology / Q000633:toxicity*; D015849:Plasminogen Inactivators / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D018180:Thrombomodulin / Q000187:drug effects / Q000235:genetics; D013925:Thromboplastin / Q000187:drug effects / Q000235:genetics; D050257:Tubulin Modulators / Q000494:pharmacology / Q000633:toxicity*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000633:toxicity*
D016207:Cytokines; D009566:Nitrates; D015849:Plasminogen Inactivators; D011506:Proteins; D018180:Thrombomodulin; D050257:Tubulin Modulators; D014409:Tumor Necrosis Factor-alpha; D013925:Thromboplastin; D017239:Paclitaxel